Paris

• PRODIGE 111 – DOMZIGAST A randomized phase II study evaluating FOLFIRI vs FOLFIRI plus Domvanalimab (anti-TIGIT) and Zimberelimab (anti-PD1) … Ended
  2024-519258-35-00 4 stomach cancer
• A trial to find out how well CVHNLC works at different dose levels and how safe it is in combination with pembrolizumab in patients with lun … Ended
  2024-519651-28-00 1 metastatic squamous non-small cell lung cancer
• Study of the Effectiveness and Safety of Acasunlimab Alone or With Pembrolizumab in treating Advanced Melanoma of the Skin That Has Returned … Ended
  2025-520468-16-00 4 Cutaneous Melanoma, Relapsed/Refractory, Locally Advanced Unresectable
• A Phase 1/1b Open-Label Dose-Escalation and Dose-Optimization Study of Bcl-2 Inhibitor BGB 21447 in Patients With Mature B Cell Malignancies Ended
  2025-521600-21-00 1 mature B-Cell malignancies
• A study of lifileucel (tumor-infiltrating lymphocytes) in adults with advanced melanoma Ended
  2025-522054-40-00 4 Previously treated advanced melanoma
• WALKALS : A pilot phase II study to evaluate the effect of salbutamol on walking capacity in ambulatory ALS patients. Expired
  2022-501624-14-00 4 Amyotrophic Lateral Sclerosis (ALS)

Showing 2,281–2,286 of 2,286 trials